Eli Lilly and Company (NYSE:LLY) Trading Down 2.8% – What’s Next?

Shares of Eli Lilly and Company (NYSE:LLY) traded down 2.8% during trading on Friday . The company traded as low as $947.51 and last traded at $948.0140. 3,048,034 shares traded hands during mid-day trading, a decline of 5% from the average session volume of 3,207,355 shares. The stock had previously closed at $974.96.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target on Eli Lilly to $900 from $880, signaling continued confidence in the company’s long-term earnings power despite the target still implying downside from recent trading levels.
• Positive Sentiment: Cantor Fitzgerald also lifted its price target after Lilly’s strong Q1 results, reflecting analyst optimism following better-than-expected earnings, revenue growth, and robust demand for GLP-1 drugs.
• Positive Sentiment: News flow around Lilly’s obesity and weight-loss pipeline remains favorable, with reports highlighting expanding market potential for GLP-1 pills and suggesting the category could reach a much larger patient base.
• Positive Sentiment: Coverage following Lilly’s quarterly earnings continued to emphasize the company’s powerful growth profile, including Mounjaro becoming the world’s best-selling drug and management’s raised full-year guidance.
• Positive Sentiment: Lilly announced an additional $4.5 billion investment in Indiana manufacturing sites, which reinforces supply-chain capacity and signals management’s confidence in future demand.
• Neutral Sentiment: Several articles focused on Lilly’s long-term upside, including bullish speculation about whether it could become a $2 trillion healthcare company; these are sentiment-positive but do not add new near-term catalysts. Article Title
• Neutral Sentiment: Shareholder approval of the board and existing governance structure removes an overhang, but is unlikely to be a major stock-moving catalyst on its own.
• Negative Sentiment: One research note and commentary on recent FDA adverse-event reporting suggest some concern around a hepatic-failure report tied to Foundayo, which could add modest regulatory headline risk even if analysts think the market reaction has been overdone.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on LLY. Daiwa Securities Group upped their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Leerink Partners dropped their price target on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating for the company in a research note on Monday, April 27th. Rothschild & Co Redburn increased their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday. HSBC cut shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price objective for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Finally, Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,218.33.

Eli Lilly and Company Stock Performance

The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock has a market cap of $892.78 billion, a price-to-earnings ratio of 33.68, a PEG ratio of 1.08 and a beta of 0.48. The stock’s fifty day moving average is $943.90 and its 200-day moving average is $990.90.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period last year, the business posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 35.68 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors have recently modified their holdings of LLY. 10Elms LLP raised its holdings in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares during the period. M.E. Allison & CO. Inc. increased its position in shares of Eli Lilly and Company by 0.7% during the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock worth $1,587,000 after acquiring an additional 10 shares in the last quarter. Tanager Wealth Management LLP increased its position in shares of Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after acquiring an additional 10 shares in the last quarter. Morey & Quinn Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 1.5% during the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock worth $710,000 after acquiring an additional 10 shares during the period. Finally, Wealthspan Partners LLC raised its holdings in shares of Eli Lilly and Company by 0.5% during the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after acquiring an additional 10 shares during the period. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.